University Hospital Ghent and VIB are testing medication to treat COVID-19-associated respiratory illness University Hospital Ghent and VIB are assessing a drug called Leukine® to treat patients with respiratory illness associated with COVID-19. Major medical centers in [...] March 25, 2020 · BioVox
Potential impact of the corona crisis on the life sciences industry Over the past few months, every news headline has focused on COVID-19. The industry is accelerating its own in-house research […] March 26, 2020 · V-Bio Ventures
Belgian clinical trials for COVID-19 With COVID-19 cases soaring into the millions, and a vaccine still a ways off, patients are desperate for a treatment. […] May 5, 2020 · BioVox
To prevent another pandemic, we need to improve our relationship with animals The new coronavirus did not come as a bolt from the blue. For many years, the World Health Organization (WHO) […] June 8, 2020 · BioVox
V-Bio invests into ExeVir Bio to accelerate development of new treatment conferring broad protection against Covid-19 Ghent, Belgium, 28 July 2020 – Today V-Bio Ventures announces its investment in a EUR 23 million Series A financing into ExeVir Bio. […] July 28, 2020 · V-Bio Ventures
Countering COVID-19 with llama antibodies In July 2020, VIB spin-off ExeVir Bio raised €23 million to advance a llama-derived antibody against COVID-19. The company is […] August 31, 2020 · BioVox
UAntwerp researchers find cause for mysterious nodding syndrome For decades, researchers have been trying to uncover the cause of nodding syndrome, a mysterious and deadly form of epilepsy […] September 30, 2020 · BioVox
V-Bio Ventures invests in new start-up Animab in a EUR 3.4 million Seed Financing to improve health and performance of livestock animals Gent, Belgium, 27 October 2020 – Today V-Bio Ventures announces its investment in Animab, a new venture spin-off from VIB, in a EUR […] October 27, 2020 · V-Bio Ventures
eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities Niel, Belgium, 1 December 2020 – eTheRNA immunotherapies NV (“eTheRNA”) announced it has entered into a strategic cooperation and product […] December 2, 2020 · Quality by Design - Business & Communications
One year of COVID-19: a look back at 2020 and where we are now One year on from the emergence of SARS-COV-2 in Wuhan, China, this novel coronavirus continues to devastate the world. Since […] January 27, 2021 · BioVox
Preventive saliva test for detecting the COVID-19 virus is now available to companies and organizations Ghent, Belgium, 23 February 2021 – The Ghent company Biogazelle and the medical laboratory Labo Nuytinck (Ghent, Evergem), together with […] February 23, 2021 · Quality by Design - Business & Communications
Record-breaking pollen levels linked to increased risk of COVID-19 Increased pollen concentrations are correlated with higher rates of COVID-19. Hot on the heels of record-breaking European pollen counts, this […] March 10, 2021 · BioVox
Lessons learned from COVID-19: how do we prepare for the next pandemic? Although the crisis has not yet passed, COVID-19 has already taught us many valuable lessons. This past year has tested […] March 10, 2021 · Quality by Design - Business & Communications
Malaria vaccine candidate shows promise for African children Despite decades of research, scientists have so far been unable to develop a fully effective vaccine for malaria. Now, a […] June 16, 2021 · BioVox
Moderna: from secretive platform company to vaccine superstar Moderna Therapeutics has never really been a typical biotech. Sure, nowadays it is world famous thanks to its COVID-19 vaccine, […] June 23, 2021 · V-Bio Ventures